Cargando…

Risk Factors for Anthracycline-Induced Cardiotoxicity in Breast Cancer Treatment: A Meta-Analysis

BACKGROUND: Anthracyclines play an important role in the treatment of breast cancer (BC) and other malignant tumors. However, accompanied side-effects are non-ignorable. The purpose of this meta-analysis is to determine the risk factors for anthracycline-induced cardiotoxicity (ACT), so as to identi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Meilin, Yang, Hongguang, Xu, Changcun, Jin, Feng, Zheng, Ang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9248259/ https://www.ncbi.nlm.nih.gov/pubmed/35785172 http://dx.doi.org/10.3389/fonc.2022.899782

Ejemplares similares

Risk Factors for Anthracycline-Induced Cardiotoxicity
por: Qiu, Shuo, et al.
Publicado: (2021)

Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan
por: Shaikh, Abdul Sattar, et al.
Publicado: (2013)

Risk factors from Framingham risk score for anthracyclines cardiotoxicity in breast cancer: A systematic review and meta-analysis
por: Jin, Hao, et al.
Publicado: (2023)

Metabolic Aspects of Anthracycline Cardiotoxicity
por: Russo, Michele, et al.
Publicado: (2021)

Cardiotoxicity of Anthracyclines
por: Cardinale, Daniela, et al.
Publicado: (2020)

Anthracycline-induced cardiotoxicity and senescence
por: Booth, Laura K., et al.
Publicado: (2022)

Cardioprotection in Patients at High Risk of Anthracycline-Induced Cardiotoxicity: JACC: CardioOncology Primer
por: Henriksen, Peter A., et al.
Publicado: (2023)

Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment
por: Cai, Fengfeng, et al.
Publicado: (2019)

Anthracycline Chemotherapy and Cardiotoxicity
por: McGowan, John V, et al.
Publicado: (2017)

Novel Therapeutics for Anthracycline Induced Cardiotoxicity
por: Vuong, Jacqueline T., et al.
Publicado: (2022)

Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment
por: Volkova, Maria, et al.
Publicado: (2011)

Racial Disparity in Anthracycline-induced Cardiotoxicity in Breast Cancer Patients
por: Balaji, Swetha, et al.
Publicado: (2023)

The role of iron in anthracycline cardiotoxicity
por: Gammella, Elena, et al.
Publicado: (2014)

Updates in Anthracycline-Mediated Cardiotoxicity
por: Nebigil, Canan G., et al.
Publicado: (2018)

Genetics of Anthracycline-Associated Cardiotoxicity
por: Al-Otaibi, Talal Khalid, et al.
Publicado: (2022)

Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
por: Chung, Woo-Baek, et al.
Publicado: (2016)

Anthracycline-Induced Cardiotoxicity: Remembering the Forgotten Ventricle
por: Liu, Jennifer E.
Publicado: (2020)

The Quest for an Early Marker of Anthracycline-Induced Cardiotoxicity
por: Ibanez, Borja, et al.
Publicado: (2022)

Epigenetic Changes Associated With Anthracycline‐Induced Cardiotoxicity
por: Tantawy, Marwa, et al.
Publicado: (2020)

Cardiac MRI assessment of anthracycline-induced cardiotoxicity
por: Mabudian, Leila, et al.
Publicado: (2022)

Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity
por: Sobiborowicz-Sadowska, Aleksandra M., et al.
Publicado: (2023)

Efficacy of Dexrazoxane in Preventing Anthracycline Cardiotoxicity in Breast Cancer
por: Macedo, Ariane V.S., et al.
Publicado: (2019)

Influencing factors of anthracycline-induced subclinical cardiotoxicity in acute leukemia patients
por: Zhou, Xi, et al.
Publicado: (2023)

Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients
por: Bulten, Ben F., et al.
Publicado: (2015)

The Beneficial Role of Physical Exercise on Anthracyclines Induced Cardiotoxicity in Breast Cancer Patients
por: Tranchita, Eliana, et al.
Publicado: (2022)

Molecular mechanisms of anthracycline induced cardiotoxicity: Zebrafish come into play
por: Moossavi, Maryam, et al.
Publicado: (2023)

Intracellular magnesium concentrations and acute anthracycline-induced cardiotoxicity.
por: Sartori, S., et al.
Publicado: (1991)

Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
por: Henninger, Christian, et al.
Publicado: (2017)

Mechanisms of Anthracycline-Induced Cardiotoxicity: Is Mitochondrial Dysfunction the Answer?
por: Murabito, Alessandra, et al.
Publicado: (2020)

Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
por: Bansal, Neha, et al.
Publicado: (2019)

Cardiotoxicity of anthracycline therapy: current perspectives
por: Valcovici, Mihaela, et al.
Publicado: (2016)

Coronary microcirculation damage in anthracycline cardiotoxicity
por: Galán-Arriola, Carlos, et al.
Publicado: (2021)

Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity
por: Araujo-Gutierrez, Raquel, et al.
Publicado: (2021)

Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk
por: Gómez-Vecino, Aurora, et al.
Publicado: (2023)

Intermediate Molecular Phenotypes to Identify Genetic Markers of Anthracycline-Induced Cardiotoxicity Risk
por: Gómez-Vecino, Aurora, et al.
Publicado: (2023)

Preventive use of beta-blockers for anthracycline-induced cardiotoxicity: A network meta-analysis
por: He, Dongsheng, et al.
Publicado: (2022)

Platycodon grandiflorum Protects Against Anthracycline-Induced Cardiotoxicity in Early Breast Cancer Patients
por: Hao, Wei, et al.
Publicado: (2020)

Cardiotoxicity After Anthracycline Chemotherapy for Childhood Cancer in a Multiethnic Asian Population
por: Tan, Varen Zhi Zheng, et al.
Publicado: (2021)

Anthracycline-induced cardiotoxicity and the cardiac-sparing effect of liposomal formulation
por: Rahman, Atiar M, et al.
Publicado: (2007)

Cardiac magnetic resonance characteristics of acute anthracycline-induced cardiotoxicity
por: Toro-Salazar, Olga H, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0s2mmli4jgvn5p2pcu029put6f